A same day α-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens

Area of Science:

• Neuroscience
• Biochemistry
• Medical Diagnostics

Background:

• Synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB), are defined by abnormal alpha-synuclein aggregation.
• Current alpha-synuclein seed amplification assays (SAA) offer high diagnostic accuracy but require over 48 hours for results.
• Accelerating diagnostic timelines is crucial for timely intervention and therapeutic development.

Purpose of the Study:

• To develop a significantly faster alpha-synuclein RT-QuIC assay for diagnosing synucleinopathies.
• To maintain or improve the analytical sensitivity of existing alpha-synuclein seed amplification assays.
• To enhance the clinical utility and throughput of alpha-synuclein detection.

Main Methods:

• Development and validation of a novel, rapid alpha-synuclein RT-QuIC assay.
• Testing the assay's performance on various biospecimens including brain, skin, intestinal mucosa, and cerebrospinal fluid (CSF).
• Comparison of assay speed and sensitivity against established RT-QuIC protocols.

Main Results:

• The new same-day alpha-synuclein RT-QuIC (sdRT-QuIC) assay achieves high analytical sensitivity comparable to slower methods.
• Positive results were obtained in under 12 hours for brain, skin, and intestinal mucosa samples, often within 5 hours.
• CSF samples yielded positive signals within a few hours longer than peripheral tissues.

Conclusions:

• The sdRT-QuIC assay provides a rapid, sensitive, and specific diagnostic tool for synucleinopathies.
• This accelerated assay improves the practicality and cost-effectiveness of detecting pathological alpha-synuclein.
• The sdRT-QUIC assay has significant potential for research, clinical diagnosis, and advancing therapeutic strategies for synucleinopathies.